Form Type:  SC 13G
Filing Date:  9/10/2019 
CIK:  0001759425 
Address:  950 TOWER LANE, SUITE 1050 
City, State, Zip:  FOSTER CITY, California 94404 
Telephone:  650-667-4085 
Fiscal Year:  12/31 
Last Trade
Last Trade: 
-0.40 (-4.18%)  
Trade Time: 
Dec 11  
Market Cap: 
Trade MIRM now with 

© 2019  
Description of Business
We are a biopharmaceutical company focused on the development and commercialization of a late-stage pipeline of novel therapies for debilitating liver diseases. We focus on diseases for which the unmet medical need is high and the biology for treatment is clear. Our pipeline consists of two clinical-stage product candidates with mechanisms of action that have potential utility across a wide range of orphan liver diseases. We are initially developing maralixibat for the treatment of pediatric patients with progressive familial intrahepatic cholestasis, or PFIC, and Alagille syndrome, or ALGS. Based on improvements in pruritus, or itching, and other disease markers observed in Phase 2 clinical trials, we commenced enrollment in the Phase 3 MARCH clinical trial in PFIC in the second quarter of 2019 and are planning to initiate a Phase 3 clinical trial in ALGS in the first half of 2020.
Register and access this filing in:     
  EXHIBIT 99.1
  EXHIBIT 99.2